Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-02-22
Target enrollment:
Participant gender:
Summary
This is an open phase I clinical study to evaluate the safety, tolerability, pharmacokinetic
(PK) profile, pharmacodynamic (PD) profile, immunogenicity, and preliminary efficacy of JS203
in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. The study is divided into
three phases: a dose-escalation phase, a dose-expansion phase, and an efficacy expansion
phase.